These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 16464183

  • 1. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
    Biddle AK, Simpson KN.
    Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
    [Abstract] [Full Text] [Related]

  • 2. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
    Mauskopf J, Lacey L, Kempel A, Simpson K.
    Am J Manag Care; 1998 Jul; 4(7):1004-12. PubMed ID: 10181990
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD, Holtgrave DR, Pinkerton HJ.
    Arch Intern Med; 1997 Sep 22; 157(17):1972-80. PubMed ID: 9308509
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM, Tsevat J.
    Med Decis Making; 2004 Sep 22; 24(1):30-9. PubMed ID: 15005952
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
    Simpson KN, Rajagopalan R, Dietz B.
    Adv Ther; 2009 Feb 22; 26(2):185-93. PubMed ID: 19219410
    [Abstract] [Full Text] [Related]

  • 6. [Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients].
    Pinto JL, López Lavid C, Badia X, Coma A, Benavides A.
    Med Clin (Barc); 2000 Feb 22; 114 Suppl 3():62-7. PubMed ID: 10994566
    [Abstract] [Full Text] [Related]

  • 7. Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States.
    Pinkerton SD, Holtgrave DR, Layde PM.
    Prev Med; 2000 Jan 22; 30(1):64-9. PubMed ID: 10642461
    [Abstract] [Full Text] [Related]

  • 8. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct 22; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

  • 9. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
    Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A, Nguyen BY, Chodakewitz J, Mellors J.
    AIDS Res Hum Retroviruses; 1999 Apr 10; 15(6):499-508. PubMed ID: 10221527
    [Abstract] [Full Text] [Related]

  • 10. [A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
    Zheng YH, Yang X, Chang WH.
    Hunan Yi Ke Da Xue Xue Bao; 2003 Aug 10; 28(4):390. PubMed ID: 14653126
    [No Abstract] [Full Text] [Related]

  • 11. Nevirapine triple combo results released.
    Common Factor; 1995 Apr 10; (no 10):21. PubMed ID: 11362346
    [Abstract] [Full Text] [Related]

  • 12. Viramune triple therapy shows suppression of HIV after 1 year, 7 months.
    AIDS Patient Care STDS; 1997 Dec 10; 11(6):456-7. PubMed ID: 11361871
    [No Abstract] [Full Text] [Related]

  • 13. Economic impact of delaying or preventing AIDS in persons with HIV.
    Pinkerton SD, Holtgrave DR.
    Am J Manag Care; 1999 Mar 10; 5(3):289-98. PubMed ID: 10351025
    [Abstract] [Full Text] [Related]

  • 14. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E, Saba J, Muyingo S, Kahn JG.
    AIDS; 2006 Apr 04; 20(6):907-14. PubMed ID: 16549976
    [Abstract] [Full Text] [Related]

  • 15. Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
    Int J STD AIDS; 1999 Jun 04; 10(6):357-62. PubMed ID: 10414877
    [Abstract] [Full Text] [Related]

  • 16. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S, Antunes OA, Fortunak JM.
    Antiviral Res; 2008 Sep 04; 79(3):143-65. PubMed ID: 18571246
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV.
    Pinkerton SD, Holtgrave DR, Bloom FR.
    AIDS; 1998 Jun 18; 12(9):1067-78. PubMed ID: 9662204
    [Abstract] [Full Text] [Related]

  • 18. The economics of effective AIDS treatment in Thailand.
    Over M, Revenga A, Masaki E, Peerapatanapokin W, Gold J, Tangcharoensathien V, Thanprasertsuk S.
    AIDS; 2007 Jul 18; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.